These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39206515)

  • 1. Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy.
    Sandoval ML; Rishi A; Latifi K; Grass GD; Torres-Roca J; Rosenberg SA; Yamoah K; Johnstone PAS
    Cancer Control; 2024; 31():10732748241270595. PubMed ID: 39206515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results.
    Sandoval ML; Youssef I; Latifi K; Grass GD; Torres-Roca J; Rosenberg S; Yamoah K; Johnstone PA
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
    Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
    Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
    Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
    Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.
    Poon DMC; Yuan J; Yang B; Wong OL; Chiu ST; Chiu G; Cheung KY; Yu SK; Yung RWH
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
    Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
    Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer.
    Moore A; Kollmeier MA; McBride SM; Toumbacaris N; Zhang Z; Lacy-Elsayegh A; Dreyfuss A; Grossman CE; Gorovets D; Zelefsky MJ
    Eur Urol Oncol; 2024 Aug; 7(4):812-820. PubMed ID: 37949730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer.
    Poon DMC; Yuan J; Wong OL; Yang B; Tse MY; Lau KK; Chiu ST; Chiu PK; Ng CF; Chui KL; Kwong YM; Ma WK; Cheung KY; Chiu G; Yu SK
    World J Urol; 2024 Feb; 42(1):97. PubMed ID: 38393414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.
    Cuccia F; Mazzola R; Nicosia L; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Mantoan B; De Simone A; Sicignano G; Ruggieri R; Cavalleri S; Alongi F
    Radiat Oncol; 2020 Jul; 15(1):178. PubMed ID: 32698843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.
    Poiset SJ; Shah S; Cappelli L; Anné P; Mooney KE; Werner-Wasik M; Laufer TS; Posey JA; Lin D; Basu Mallick A; Lavu H; Bashir B; Yeo CJ; Mueller AC
    Radiat Oncol; 2024 May; 19(1):65. PubMed ID: 38812040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer.
    Mazzola R; Sicignano G; Cuccia F; Vitale C; Rigo M; Giaj-Levra N; Nicosia L; Figlia V; Ricchetti F; Attinà G; Pastorello E; De Simone A; Gurrera D; Naccarato S; Ruggieri R; Alongi F
    Br J Radiol; 2021 Oct; 94(1126):20210521. PubMed ID: 34283646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
    Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
    Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.